The stock of AnaptysBio Inc (NASDAQ: ANAB) has decreased by -7.64 when compared to last closing price of 21.47.Despite this, the company has seen a loss of -19.81% in its stock price over the last five trading days. InvestorPlace reported 2024-04-15 that The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.
Is It Worth Investing in AnaptysBio Inc (NASDAQ: ANAB) Right Now?
Moreover, the 36-month beta value for ANAB is -0.27. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANAB is 23.71M and currently, short sellers hold a 18.15% of that float. On April 19, 2024, ANAB’s average trading volume was 325.30K shares.
ANAB’s Market Performance
The stock of AnaptysBio Inc (ANAB) has seen a -19.81% decrease in the past week, with a -14.78% drop in the past month, and a -16.29% fall in the past quarter. The volatility ratio for the week is 7.86%, and the volatility levels for the past 30 days are at 6.63% for ANAB. The simple moving average for the past 20 days is -9.41% for ANAB’s stock, with a -1.20% simple moving average for the past 200 days.
Analysts’ Opinion of ANAB
Many brokerage firms have already submitted their reports for ANAB stocks, with Leerink Partners repeating the rating for ANAB by listing it as a “Outperform.” The predicted price for ANAB in the upcoming period, according to Leerink Partners is $47 based on the research report published on April 16, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $56. The rating they have provided for ANAB stocks is “Overweight” according to the report published on April 11th, 2024.
Wedbush gave a rating of “Outperform” to ANAB, setting the target price at $34 in the report published on March 12th of the current year.
ANAB Trading at -15.25% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.89% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 7.86%, as shares sank -17.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.44% lower at present.
During the last 5 trading sessions, ANAB fell by -19.81%, which changed the moving average for the period of 200-days by +1.07% in comparison to the 20-day moving average, which settled at $21.68. In addition, AnaptysBio Inc saw -7.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from Faga Daniel, who sale 3,000 shares at the price of $21.42 back on Mar 25 ’24. After this action, Faga Daniel now owns 749,087 shares of AnaptysBio Inc, valued at $64,268 using the latest closing price.
Faga Daniel, the CEO of AnaptysBio Inc, sale 145,940 shares at $22.78 during a trade that took place back on Mar 22 ’24, which means that Faga Daniel is holding 752,087 shares at $3,325,185 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -9.58 for the present operating margin
- 0.86 for the gross margin
The net margin for AnaptysBio Inc stands at -9.78. The total capital return value is set at -0.4. Equity return is now at value -93.44, with -30.79 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -9.09.
Currently, EBITDA for the company is -135.82 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 29.87. The receivables turnover for the company is 2.5for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.87.
Conclusion
To wrap up, the performance of AnaptysBio Inc (ANAB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
